SLC5A2 and myocardial infarction: Among patients in the SGLT2 inhibitor arm, 7,623 (56.8%) received early treatment (within eight weeks after MI), while 5,797 (43.2%) had a history of MI and received delayed treatment (at least eight weeks following MI).